Plasma membrane STIM1 as a new therapeutic target for SLE and CLL - Techno Market

Offre n°2236
Plasma membrane STIM1 as a new therapeutic target for SLE and CLL

L'innovation

The invention relates to the use of the fraction of STIM1 localized to the plasma membrane as a therapeutic target in CLL and SLE by modulating its presence or its activity.

Chronic lymphocytic leukemia (CLL) is the leading cause of leukemia in Western countries. To date, no treatment including the novel therapies targeting the B cell receptor (BCR) pathway (e.g. anti-CD20 monoclonal antibodies (mAb), BCR kinase inhibitors) offers a complete remission. It is noteworthy that the rate of treatment interruptions and toxicity remain elevated for these patients.

Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by the presence of autoreactive lymphocytes and of antinuclear auto-antibodies (ANA). It is a multisystemic disease, with heterogenous clinical manifestations. SLE may affect all organs.

Ses bénéfices

  • Presence of the marker solely on affected cells
  • Expression by the immune cells of the STIM1 protein at the plasma membrane facilitates the accessibility of this target

Ses applications

  • Autoimmune diseases
  • Cancer
Intéressé par cette offre ?
Contactez Hervé LE DEIT
Télécharger PDF Favoris

Stade de développement

  • IN VIVO - Preuve de concept
  • Pré - clinique

Laboratoire de recherche

UMR 1227 - LBAI

Équipe de recherche

LYMPHOCYTES B ET AUTOIMMUNITÉ

Propriété intellectuelle associée

EP : EP14290232 - filed on the 08-06-2014
WO - AT,BE,BE,CA,CH,CH,CN,DE,DE,DK,EP,ES,FI,FR,FR,GB,GB,GR,
IE,IE,IT,JP,LU,NL,NO,PL,PT,SE,TR,US

Créer une notification

Recevez les prochaines offres qui correspondent à vos besoins.
Merci pour l’intérêt que vous portez aux innovations proposées par la SATT Ouest Valorisation.
Nous ne manquerons pas de vous informer, par email, des futures innovations correspondant à votre besoin.
Pour toute autre demande, faites votre demande ICI.